Form 4: IO Biotech CFO Amy Sullivan Reports Stock Option Grant
SEC Filing
Amy Sullivan, CFO of IO Biotech, Inc., reports the acquisition of stock options.
Summary
- Amy Sullivan, the Chief Financial Officer of IO Biotech, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on March 15, 2024.
- Sullivan acquired 280,000 stock options with an exercise price of $1.65.
- The options vest over time, with one-fourth vesting on March 15, 2025, and the remainder vesting monthly thereafter, subject to continued service.
- The options have accelerated vesting under certain termination scenarios.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option grants to the CFO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.
Stakeholder Impact
- The grant of stock options aligns the CFO's interests with those of the shareholders, incentivizing her to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of the stock option grant. |
| 03/15/2025 | Date when one-fourth of the options vest. |
| 03/18/2024 | Date of the Form 4 filing. |
| 03/15/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.